Latest Renal function Stories

Markers may transform how kidney disease is diagnosedAcute kidney injury (AKI) is a common "“ but preventable -- complication after surgery that can lead to other complications or even death. The use and development of biomarkers will help physicians diagnose and treat acute kidney injury. Three protein measurements indicate who has a high risk of developing kidney injury after heart surgery, according to two studies appearing in an upcoming issue of the Journal of the American Society of...

JAMA paper could reverse long-standing guidelines and advice for African-American patients with kidney diseaseFor years, medical studies have reached the same conclusion: African-American patients do better on kidney dialysis than their white counterparts. But new Johns Hopkins research, published in the Journal of the American Medical Association, shows that younger blacks "” those under the age of 50 "” actually do much worse on dialysis than equally sick whites who undergo the same...

EAST NORRITON, Pa., Aug. 9, 2011 /PRNewswire/ -- Tengion, Inc. (Nasdaq: TNGN) today provided a business update and reported its financial results for the second quarter ended June 30, 2011. "This is an important time for Tengion as we continue to make progress on our lead clinical and preclinical programs, as well as on our corporate and partnership strategy," said David Scheer, chairman of the Tengion board of directors. "Our search for a new chief executive officer is underway and our...

MARKHAM, ON, July 26, 2011 /PRNewswire/ - Cytochroma today announced that it has closed an equity investment of $1 million from the Investment Accelerator Fund, a fund of the Province of Ontario that invests in emerging Ontario technology companies.  The investment is designed to advance and accelerate the Company's development of CTAP101 Capsules, a product currently in a Phase 2b study for the treatment of secondary hyperparathyroidism associated with vitamin D insufficiency...

Clinical studies confirm linagliptin's efficacy and tolerability in combination therapy with metforminBoehringer Ingelheim and Lilly today announced Phase III study results for linagliptin*, demonstrating improved glycemic control in adults with type 2 diabetes (T2D) whose blood glucose is not adequately controlled on current therapy. In one long-term study over two years evaluating linagliptin or glimepiride when added to metformin, linagliptin was effective at lowering blood glucose, as...

IRVING, Texas and ABBOTT PARK, Ill., June 24, 2011 /PRNewswire/ -- New Phase 2 clinical trial data published online today in The New England Journal of Medicine show that patients with moderate to severe chronic kidney disease and type 2 diabetes receiving bardoxolone methyl for 52 weeks experienced a sustained improvement in kidney function throughout the treatment period, as measured by estimated glomerular filtration rate (eGFR). The data were also presented today in a Late-Breaking...

(Ivanhoe Newswire)--Diabetic Kidney Disease, or DKD, is a common complication of diabetes and leading cause of chronic kidney disease and is becoming more prevalent in the U.S. About forty percent of people diagnosed with diabetes develop DKD."Over time, the prevalence of DKD may increase due to the expanding size of the diabetes population or decrease due to the implementation of diabetes therapies," the author's of a recent study were quoted saying.Most people with DKD also have...

Over the past 2 decades the prevalence of diabetic kidney disease in the U.S. increased in direct proportion to the prevalence of diabetes itself, according to a study in the June 22/29 issue of JAMA.Diabetic kidney disease (DKD) is a common complication of diabetes and the leading cause of chronic kidney disease in the developed world. Approximately 40 percent of persons with diabetes develop DKD, which also accounts for nearly half of all new cases of end-stage renal disease (ESRD) in the...

IRVING, Texas and ABBOTT PARK, Ill., June 16, 2011 /PRNewswire/ -- Reata Pharmaceuticals, Inc. and Abbott announced today the initiation of a pivotal Phase 3 clinical trial to evaluate the safety and efficacy of bardoxolone methyl in patients with chronic kidney disease (eGFR of 15-29 mL/min/1.73 m2) and type 2 diabetes. The trial, known as BEACON (Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes: the Occurrence of renal eveNts), is the first...

MONHEIM, Germany, May 19, 2011 /PRNewswire/ -- - Online Campaign Fronted by Garfield Launches to Educate the Owners of Middle Aged Cats About Chronic Kidney Disease A new campaign launched today will educate cat owners about the risk of chronic kidney disease (CKD) that their pets may face as they grow older and urge them to seek kidney function tests for cats over the age of seven. A brand new animation featuring Garfield (as licensed by Paws Inc.) in the midst of a mid-life...